Company intelligence / Profile preview

F-star Gamma

Cambridge, United Kingdom

Ownership: Private
Development stage: Other

Overview

F-star Gamma was an asset-centric subsidiary of F-star Therapeutics that developed preclinical bispecific antibodies (Fcabs) for crossing the blood-brain barrier. It was acquired by Denali Therapeutics in 2018 following preclinical proof of concept focused on neurodegenerative disease targets.

Therapeutic areas: OncologyNeurology
Modalities: AntibodyBispecific monoclonal antibody
Industry: Biotech

Partnerships

Denali TherapeuticsTakeda Pharmaceutical Company

Beyond the preview

Go deeper on F-star Gamma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-star Gamma.

Explore the full profile